Sustained efficacy of adefovir add-on therapy in chronic hepatitis B patient with a poor virological response to peginterferon alfa

EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection

(2015)   JOURNAL OF HEPATOLOGY

Chronic Inflammatory Demyelinating Polyneuropathy Due to the Administration of Pegylated Interferon α-2b: A Neuropathology Case Report

(2012) Kensuke Shiga et al.   INTERNAL MEDICINE

Peginterferon alpha-based therapy for chronic hepatitis B focusing on HBsAg clearance or seroconversion: a meta-analysis of controlled clinical trials

(2011) Wen-cong Li et al.   BMC INFECTIOUS DISEASES

Hepatitis B Virus Serology to Predict Antiviral Response in Chronic Hepatitis B

(2011) Beom Kyung Kim et al.   DIGESTION

Pegylated-interferon-α2ain clinical practice: how to manage patients suffering from side effects

(2011) Vincenza Calvaruso et al.   Expert Opinion On Drug Safety

A randomized controlled trial of pegylated interferon-α2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B

(2009) Paola Piccolo et al.   ANTIVIRAL THERAPY

Peginterferon-α-2a (40 kD)

(2009) Gillian M. Keating   DRUGS

Chronic hepatitis B: Update 2009

(2009) Anna S. F. Lok et al.   HEPATOLOGY

Review article: current antiviral therapy of chronic hepatitis B

(2008) W. S. AYOUB et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B

(2008) Michael W. Fried et al.   HEPATOLOGY

The Roadmap concept: using early on-treatment virologic responses to optimize long-term outcomes for patients with chronic hepatitis B

(2008) Edward J. Gane   Hepatology International

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update

(2008) Yun-Fan Liaw et al.   Hepatology International